A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
NCT06862908 on ClinicalTrials.gov · last registry update 2025-07-11
Recruiting now, toward 141 participants. Due to report 24 September 2026, alongside 37 other tracked readouts that quarter. Primary outcome, as filed: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P2
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 141
- Started
- 2025-04-01
- Primary completion
- 2026-09-24 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
Conditions studied
Obesity · Heart Failure With Preserved Ejection Fraction (HFPEF) · Heart Failure With Mildly Reduced Ejection Fraction
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.